Log in

Relevant bibliographies by topics / B-acute lymphoblastic leukemia / Dissertations / Theses

To see the other types of publications on this topic, follow the link: B-acute lymphoblastic leukemia.

Dissertations / Theses on the topic 'B-acute lymphoblastic leukemia'

Author: Grafiati

Published: 25 May 2024

Last updated: 27 July 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 49 dissertations / theses for your research on the topic 'B-acute lymphoblastic leukemia.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse dissertations / theses on a wide variety of disciplines and organise your bibliography correctly.

1

Oliveira, Tiago M. "The importance of glycosylation in Acute Lymphoblastic Leukemia." Thesis, Griffith University, 2021. http://hdl.handle.net/10072/410463.

Full text

Abstract:

Acute leukemias, such as acute lymphoblastic leukemia (ALL), are aggressive cancers characterized by the rapid proliferation of malignant hematopoietic cells. Throughout the last 60 years, childhood ALL’s long-term survival rates increased from less than 10% to more than 90%. Despite these improvements, certain subtypes remain hard to manage (e.g. mixed lineage leukemia, MLL-r), and even new therapies frequently fail. Therefore, identifying leukemia-cell restricted antigens in these ALL subtypes remains crucial in the quest to develop novel diagnostic tools and specific treatments. Traditional

APA, Harvard, Vancouver, ISO, and other styles

2

Besada, Rana Hany. "BiTEs and CAR-Ts : immunotherapy in childhood B-cell acute lymphoblastic leukemia." Thesis, Massachusetts Institute of Technology, 2018. http://hdl.handle.net/1721.1/115699.

Full text

Abstract:

Thesis: S.M., Massachusetts Institute of Technology, Department of Biology, 2018.<br>Cataloged from PDF version of thesis.<br>Includes bibliographical references (pages 18-21).<br>B-cell acute lymphoblastic leukemia is the most common pediatric cancer, responsible for the most cancer-related deaths in children. Advances in chemotherapy over the past half-century have steadily increased the remission and survival of children with B-cell acute lymphoblastic leukemia to nearly 90%. However, the problems of minimal residual disease and relapsed and refractory disease persist. Personalized, targete

APA, Harvard, Vancouver, ISO, and other styles

3

Morisot, Sebastien. "Détermination of the frequency of leukemia stem cells in childhood precursor B cell acute lymphoblastic leukemias." Paris 11, 2009. http://www.theses.fr/2009PA11T022.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Soto-Feliciano, Yadira M. (Yadira Marie). "PHF6 is a novel regulator of B-cell identity in acute lymphoblastic leukemia." Thesis, Massachusetts Institute of Technology, 2016. http://hdl.handle.net/1721.1/103165.

Full text

Abstract:

Thesis: Ph. D., Massachusetts Institute of Technology, Department of Biology, 2016.<br>This electronic version was submitted by the student author. The certified thesis is available in the Institute Archives and Special Collections.<br>Cataloged from student-submitted PDF version of thesis. Vita.<br>Includes bibliographical references.<br>Mutations in the zinc finger gene PHF6 are seen in approximately 20% of adult T-cell acute lymphoblastic leukemias and 3% of adult acute myeloid leukemias. The notable absence of PHF6 mutations in B-cell lineage malignancies has led to the hypothesis that PH

APA, Harvard, Vancouver, ISO, and other styles

5

James, Alva Rani [Verfasser]. "LncRNAs signature defining major subtypes of B-cell acute lymphoblastic leukemia / Alva Rani James." Berlin : Medizinische Fakultät Charité - Universitätsmedizin Berlin, 2019. http://d-nb.info/1189140330/34.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Nicoletti, Simon. "Natural Killer Cells and Pre-B Acute Lymphoblastic Leukemia : Evidence for an Unconventional Cytotoxicity Pathway." Thesis, Université Paris-Saclay (ComUE), 2017. http://www.theses.fr/2017SACLS383.

Full text

Abstract:

Les cellules Natural Killer (NK) représentent une population de cellules innées lymphoïdes aux fonctions anti-infectieuses et antitumorales. Les leucémies aiguës lymphoblastiques pré-B (LAL pré-B) constituent le cancer de l’enfant le plus fréquent et ont été décrites comme résistantes à la cytotoxicité médiée par les NK bien que les bases moléculaires demeurent inconnues.L’objectif de ces travaux a été de caractériser cette résistance. En développant un essai de cytotoxicité par cytométrie en flux et en utilisant des cellules effectrices activées in vitro, nous avons établi la sensibilité reta

APA, Harvard, Vancouver, ISO, and other styles

7

Ueno, Hiroo. "Landscape of driver mutations and their clinical impacts in pediatric B-cell precursor acute lymphoblastic leukemia." Doctoral thesis, Kyoto University, 2021. http://hdl.handle.net/2433/263562.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

Sartor, Chiara <1988&gt. "Research of predictive biomarkers to anti-CD22 antibody-drug conjugate treatment in B-cell acute lymphoblastic leukemia." Doctoral thesis, Alma Mater Studiorum - Università di Bologna, 2022. http://amsdottorato.unibo.it/10252/1/PhD%20thesis_Chiara%20Sartor_XXXIV%20ciclo.pdf.

Full text

Abstract:

Background: The treatment of B-cell acute lymphoblastic leukemia (B-ALL) has been enriched by novel agents targeting surface markers CD19 and CD22. Inotuzumab ozogamicin (INO) is a CD22-calicheamicin conjugated monoclonal antibody approved in the setting of relapse/refractory (R/R) B-ALL able to induce a high rate of deep responses, not durable over time. Aims: This study aims to identify predictive biomarkers to INO treatment in B- ALL by flow cytometric analysis of CD22 expression and gene expression profile. Materials and methods: Firstly, the impact on patient outcome in 30 R/R B-ALL pa

APA, Harvard, Vancouver, ISO, and other styles

9

Auer, Franziska [Verfasser], Arndt [Gutachter] Borkhardt, and Hermann [Gutachter] Aberle. "Paired Box 5 (PAX5) in B cell precursor acute lymphoblastic leukemia / Franziska Auer ; Gutachter: Arndt Borkhardt, Hermann Aberle." Düsseldorf : Universitäts- und Landesbibliothek der Heinrich-Heine-Universität Düsseldorf, 2017. http://d-nb.info/1123197628/34.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

Groeneveld-Krentz, Stefanie [Verfasser]. "The clinical relevance of aneuploidy in relapses of pediatric B-cell precursor acute lymphoblastic leukemia / Stefanie Groeneveld-Krentz." Berlin : Medizinische Fakultät Charité - Universitätsmedizin Berlin, 2020. http://d-nb.info/1223927180/34.

Full text

APA, Harvard, Vancouver, ISO, and other styles

11

SARNO, JOLANDA. "Cell signaling in high risk childhood B cell precursor acute lymphoblastic leukemia: high-throughput dissection and targeting strategies." Doctoral thesis, Università degli Studi di Milano-Bicocca, 2016. http://hdl.handle.net/10281/116109.

Full text

Abstract:

Acute lymphoblastic leukemia is the most common childhood tumor and about 85% of cases are due to the expansion of a clone of B-cell precursors (BCP-ALL). Steady progress in development of effective treatments has led to an elevated rate of success in treating this disease. To date, even thought about 75% of patients are cured, 25% of cases having a relapse has a survival probability of only 30%. Of note, more than 50% of relapses concern patients not classified in high-risk groups based on assessment of prognostic factors at diagnosis or on measurement of Minimal Residual Disease (MRD), a s

APA, Harvard, Vancouver, ISO, and other styles

12

Weilg, Claudia, Aguila Olguita Del, Fernando Mazulis, et al. "Seronegative disseminated Bartonella spp. infection in an immunocompromised patient." Elsevier B.V, 2016. http://hdl.handle.net/10757/620831.

Full text

Abstract:

An 11 year old, hispanic girl with a history of B-cell acute lymphoblastic leukemia was admitted to the hospital for symptoms compatible with Bartonella henselae infection. The first molecularly diagnosed case of disseminated Bartonella henselae infection was reported in an immunocompromised patient in Lima, Peru. The analysis was confirmed by Polymerase Chain Reaction and automated sequencing of a liver biopsy sample, even though the serologic tests were negative. In conclusion, Bartonella spp. infection should have a particular diagnostic consideration in immunocompromised patients with feve

APA, Harvard, Vancouver, ISO, and other styles

13

TURAZZI, NICE. "BAFF RECEPTOR (BAFF-R) CAR-REDIRECTED T CELLS: A NOVEL TOOL TO TREAT HIGH RISK B -CELL ACUTE LYMPHOBLASTIC LEUKEMIA (B-ALL)." Doctoral thesis, Università degli Studi di Milano-Bicocca, 2017. http://hdl.handle.net/10281/153238.

Full text

Abstract:

La leucemia linfoblastica acuta B (LLA-B) è la leucemia più comune nei bambini (80%), ma ha anche un picco di incidenza in età adulta. Recentemente, gli approcci di immunoterapia diretti contro la molecola CD19 hanno dimostrato un notevole successo nel trattamento della LLA-B recidiva e refrattaria, che rimane una delle principali necessità cliniche. Svantaggi importanti di tali strategie sono la comparsa di recidive CD19-negative e aplasia delle cellule B come risultato della persistenza delle cellule anti-CD19 CAR. In questo contesto, abbiamo ipotizzato che il recettore per il fattore di att

APA, Harvard, Vancouver, ISO, and other styles

14

Vendramini, E. "Identification of new subgroups and prognostic markers in pediatric B cell precursor acute lymphoblastic leukemia by gene expression profiling." Doctoral thesis, Università degli studi di Padova, 2010. http://hdl.handle.net/11577/3423224.

Full text

Abstract:

Treatment of pediatric acute lymphoblastic leukemia (ALL) is increasingly successful, achieving cure rates of over 80%. Early identification of patients with high risk for relapse has led to improved outcome, however, two third of patients encountering relapse were initially stratified into low-intermediate risk groups. The identification of better upfront prognostic factors remains an important challenge in childhood ALL. In this thesis, gene expression profiling (GEP) was applied to different research approaches aiming to dissect subgroups and to find novel therapeutic targets in B cell pre

APA, Harvard, Vancouver, ISO, and other styles

15

Welch, Mathew D. "Molecular mechanism underlying aberrant expression of the connective tissue growth factor in paediatric pre-B cell acute lymphoblastic leukemia." Thesis, Curtin University, 2011. http://hdl.handle.net/20.500.11937/211.

Full text

Abstract:

Acute lymphoblastic leukaemia (ALL) is the most common cancer diagnosed in children aged 1-14 years. There have been vast improvements in clinical outcomes for children diagnosed with ALL with cure rates of up to 90% achievable for some forms of the disease. Despite these successes, some patients still relapse and the prognosis for these individuals is poor, thus there is still a great deal to be learned about the complex biology underlying ALL. Connective tissue growth factor (CTGF/CCN2) is a novel candidate gene in precursor B-cell (pre-B) ALL, and is aberrantly expressed in a high proportio

APA, Harvard, Vancouver, ISO, and other styles

16

BOZZER, SARA. "Preclinical development of targeted-nanoparticles for the treatment of pediatric B-cell malignancies Acute Lymphoblastic Leukemia and Burkitt Lymphoma." Doctoral thesis, Università degli Studi di Trieste, 2022. http://hdl.handle.net/11368/3030999.

Full text

Abstract:

I tumori delle cellule B sono un gruppo eterogeneo di patologie per le quali le opzioni terapeutiche includono chemioterapia e immunoterapia. Nonostante il recente sviluppo di nuove strategie terapeutiche, la maggior parte dei pazienti, tuttavia, sviluppa resistenze o non risponde alle terapie. L'obiettivo di questo progetto di dottorato è, pertanto, lo sviluppo preclinico di un nuovo strumento terapeutico per il trattamento delle neoplasie pediatriche a cellule B. In primo luogo sono state caratterizzate le nanobolle di chitosano (NBs) caricate con AntagomiR-17, sui è stato legato un anticorp

APA, Harvard, Vancouver, ISO, and other styles

17

CRICRÌ, GIULIA. "ActivinA as a key modulator of B-Cell Precursor Acute Lymphoblastic Leukemia Cell motility and vesiculation within the bone marrow niche." Doctoral thesis, Università degli Studi di Milano-Bicocca, 2021. http://hdl.handle.net/10281/304789.

Full text

Abstract:

La Leucemia Linfoblastica Acuta (LLA) è il tumore più frequente in età pediatrica. Nonostante l’alto successo terapeutico raggiunto, una percentuale di pazienti non risponde alle terapie convenzionali. Numerosi studi hanno mostrato come il microambiente midollare giochi un importante ruolo nella progressione tumorale. Il nostro scopo è stato quello di identificare i pahways cruciali coinvolti nel cross-talk tra le cellule leucemiche e il microambiente stromale e che possano essere dei potenziali target terapeutici. Abbiamo studiato AttivinaA, molecola della superfamiglia del TGF-β, all’interno

APA, Harvard, Vancouver, ISO, and other styles

18

Duy, Cihangir Verfasser], Markus [Akademischer Betreuer] Müschen, Dieter [Akademischer Betreuer] [Willbold, and Ari [Akademischer Betreuer] Melnick. "Function of BCL6 in pre-B cells and Philadelphia chromosome-positive acute lymphoblastic leukemia / Cihangir Duy. Gutachter: Markus Müschen ; Dieter Willbold ; Ari Melnick." Düsseldorf : Universitäts- und Landesbibliothek der Heinrich-Heine-Universität Düsseldorf, 2011. http://d-nb.info/1018272461/34.

Full text

APA, Harvard, Vancouver, ISO, and other styles

19

Grain, Audrey. "Recherche de cibles antigéniques d’intérêt dans les leucémies aigües lymphoblastique B de l’enfant." Electronic Thesis or Diss., Nantes Université, 2025. http://www.theses.fr/2025NANU1003.

Full text

Abstract:

Contexte : Les anticorps monoclonaux ou les cellules CAR-T anti-CD19 autologues ont révolutionné le traitement des leucémies aigües lymphoblastique B (LAL-B) réfractaires ou en rechute. Cependant, au décours de ces thérapies ciblées, près de la moitié des patients rechutent par échappement tumoral via une modulation antigénique. Des stratégies de ciblage de plusieurs antigènes simultanément doivent être développées. Il est donc urgent d'identifier et de valider de nouvelles cibles. Méthodes : Un immunophénotypage large a été réalisé sur 13 échantillons de moelle provenant de patients pédiatriq

APA, Harvard, Vancouver, ISO, and other styles

20

Bayet, Manon. "Modélisation de la leucémie aiguë lymphoblastique B induite par la mutation PAX5 P80R." Electronic Thesis or Diss., Université de Toulouse (2023-....), 2024. http://www.theses.fr/2024TLSES005.

Full text

Abstract:

L'équipe s'intéresse aux altérations de facteurs de transcription impliquées dans les leucémies aiguës, dont PAX5 qui est essentiel pour le développement des cellules B. C'est pourquoi le modèle murin transgénique PAX5-ELN a été généré, qui exprime la protéine de fusion oncogénique durant le développement des lymphocytes B, et récapitule le processus multi-étapes des LAL-B (Jamrog L et al., PNAS, 2018). J'ai participé à l'identification des cellules à l'origine de la LAL-B et à la caractérisation de leur propriétés fonctionnelles et moléculaires. Nos travaux indiquent qu'au stade pré-leucémiqu

APA, Harvard, Vancouver, ISO, and other styles

21

KOH, THONG CHUAN EUGENE. "Down regulation of NLK by MIR-221/222 modulates chemosensitivity to glucocorticoids in pediatric normal karyotype b-cell precursor acute lymphoblastic leukemia. La downregolazione di nemo-like kinase indotta dai MIR-221/222 modula chemiosensibilità ai glucocorticoidi nella pediatrico b-cell precursor leucemia linfattica acuta." Doctoral thesis, Università degli Studi di Milano-Bicocca, 2012. http://hdl.handle.net/10281/30498.

Full text

Abstract:

Normal karyotype pediatric B-cell precursor ALL patients are heterogeneous with respect to chemotherapy response, relapse rates and prognosis and the reason is unknown. These patients are treated with a standard protocol, and stratified using MRD methodology that shows they have variable responses and predicted outcomes. This study aims to determine the reasons behind such heterogeneity. This study shows that through miRNA profiling, miR-221/222 are differentially expressed in normal karyotype patients and are up regulated in Poor Responder patients. Through proliferation, apoptosis, viability

APA, Harvard, Vancouver, ISO, and other styles

22

Pimenta, Marcela Valente. "Avaliação da resistência de formas mutantes da enzima L-asparaginase a proteases séricas humanas." Universidade de São Paulo, 2018. http://www.teses.usp.br/teses/disponiveis/9/9134/tde-10092018-173712/.

Full text

Abstract:

O tratamento para a Leucemia Linfoblástica Aguda LLA utiliza, entre outros fármacos, a enzima L-asparaginase (ASNase) proveniente da bactéria Escherichia coli. Reações imunológicas estão entre os problemas do tratamento com ASNase, e a formação de anticorpos contra essa proteína pode impedir o sucesso no tratamento. Duas cisteíno proteases lisossomais estão relacionadas com a degradação de ASNase nos seres humanos, a Catepsina B (CTSB) e Asparagina Endopeptidase (AEP). Em estudos prévios do nosso grupo obteve-se mutantes de ASNase resistentes a degradação por CTSB e/ou AEP in vitro. Nesse trab

APA, Harvard, Vancouver, ISO, and other styles

23

Ben, Abdelali Raouf. "Détection des anomalies génétiques dans les LAL-T : de la biologie à la clinique." Thesis, Paris 11, 2011. http://www.theses.fr/2011PA11T013.

Full text

Abstract:

Les leucémies aiguës lymphoblastiques T (LAL-T) sont caractérisées par la prolifération maligneincontrôlée de précurseurs lymphoïdes T bloqués dans la différenciation. Les stades d’arrêt dematuration observés dans les LAL-T reproduisent fidèlement les différentes étapes de la maturationthymique humaine. Ainsi nous avons montré que le facteur de transcription myéloïde CEBPA, expriméuniquement dans les précurseurs thymiques les plus immatures (ETP), est réprimé par un mécanismed’hyperméthylation dans les LAL-T à l’exception des formes les plus immatures. Il est aujourd’huicommunément admis que l

APA, Harvard, Vancouver, ISO, and other styles

24

Jamrog, Laura. "Impact des altérations génétiques de PAX5 sur le développement de la lignée lymphoïde B et dans la leucémogenèse des LAL-B." Electronic Thesis or Diss., Toulouse 3, 2021. http://www.theses.fr/2021TOU30306.

Full text

Abstract:

Le gène PAX5 (Paired boX 5) code un facteur de transcription essentiel pour la différenciation lymphoïde B. Nous avons montré que les deux isoformes PAX5A et PAX5B étaient différentiellement régulées mais pouvaient exercer une fonction équivalente durant l'induction de la différenciation lymphoïde B et pourraient présenter des différences fonctionnelles à la suite de l'activation des lymphocytes B. Le contrôle précis de leur expression peut ainsi refléter un moyen d'ajuster finement le dosage de PAX5 pendant le processus de différenciation des cellules de la lignée lymphoïde B. PAX5 est la cib

APA, Harvard, Vancouver, ISO, and other styles

25

Balzano-Foucher, Marielle. "Influence du microenvironnement stromal de la moelle osseuse sur le développement des lymphocytes B normaux et pathologiques." Thesis, Aix-Marseille, 2016. http://www.theses.fr/2016AIXM4048.

Full text

Abstract:

Chez l’adulte les premières étapes du développement hématopoïétique se déroulent dans la moelle osseuse (MO). La contribution de cellules d’origine mésenchymateuse, appelées niches stromales, a été démontrée dans le cas de la maintenance des cellules souches hématopoïétiques (CSH) et du développement des lymphocytes B (LB). Ainsi la maintenance des CSH dépend de niches périvasculaires sécrétant CXCL12 et SCF. Par ailleurs les LB les plus précoces (preproB) sont en contact de cellules stromales CXCL12+, puis migrent vers des cellules stromales exprimant l’interleukine-7 lors de leur différentia

APA, Harvard, Vancouver, ISO, and other styles

26

Cahu, Xavier. "Intrinsic and extrinsic factors promoting the growth of T-cell acute lymphoblastic leukemia." Paris 7, 2014. http://www.theses.fr/2014PA077218.

Full text

Abstract:

Les leucémies aiguës lymphoblastiques T (LAL-T) sont des maladies des progéniteurs T qui surviennent chez l'enfant et le jeune adulte. Des facteurs intrinsèques et extrinsèques à la cellule blastique sous-tendent le développement leucémique. Les LAL-T humaines peuvent être étudiées in vivo après injection dans des souris immunodéficientes ou in vitro dans des systèmes de cocultures avec des cellules stromales MS5 surexprimant Delta-likel. Dans la première partie de cette thèse, nous avons étudié l'hétérogénéité de croissance dans ces deux modèles. Nos résultats montrent que la croissance est p

APA, Harvard, Vancouver, ISO, and other styles

27

Gupta, Sneha Veeraraghavan. "Targeting Protein Metabolism in B-cell Malignancies." The Ohio State University, 2012. http://rave.ohiolink.edu/etdc/view?acc_num=osu1343169973.

Full text

APA, Harvard, Vancouver, ISO, and other styles

28

Catherinet, Claire. "Etude des effecteurs de la voie Ca2+/Calmoduline dans les leucémies aiguës lymphoblastiques T." Thesis, Sorbonne Paris Cité, 2017. http://www.theses.fr/2017USPCC293/document.

Full text

Abstract:

Les leucémies aigües lymphobastiques (LAL) représentent un tiers des leucémies et constituent le cancer pédiatrique le plus fréquent chez l’enfant. Les LAL de type T (LAL-T)sont caractérisées par l’expansion anormale de progéniteurs de lymphocytes T. Aujourd’hui,la réponse curative aux traitements est proche de 80% chez l’enfant et 50% chez l’adulte. La rechute reste donc fréquente et souvent de mauvais pronostic. Pour ces raisons,l’identification de nouvelles voies de signalisation en vue de développer de nouvelles stratégies thérapeutiques est cruciale afin d’améliorer le traitement des LAL-

APA, Harvard, Vancouver, ISO, and other styles

29

Rodrigues, Mariane Augusta Domingues. "Avaliação da atividade e resistência à clivagem proteolítica de L-asparaginases recombinantes obtidas por reação em cadeia da polimerase propensa a erro." Universidade de São Paulo, 2016. http://www.teses.usp.br/teses/disponiveis/9/9134/tde-24082016-163433/.

Full text

Abstract:

A L-Asparaginase II de Escherichia coli (EcA II) é uma enzima amplamente utilizada no tratamento da Leucemia Linfoblástica Aguda (LLA), atuando na depleção do aminoácido L-asparagina, o qual é fundamental para a multiplicação das células cancerosas. Contudo, o tratamento com a EcA II está associado a altos índices de hipersensibilidade, devido à formação de anticorpos anti-L-asparaginase e à clivagem da enzima pelas proteases sanguíneas asparagina endopeptidase (AEP) e catepsina B (CTSB). Também ocorre neurotoxicidade associada ao efeito L-glutaminase da enzima. O principal objetivo do present

APA, Harvard, Vancouver, ISO, and other styles

30

Della, Marina Filippo. "Dissection of the function and pre-clinical targeting of IGF1R in Acute Lymphoblastic Leukemia induced by the BCR-ABL fusion oncoprotein." Sorbonne Paris Cité, 2015. http://www.theses.fr/2015USPCC309.

Full text

Abstract:

Contrairement aux réponses cliniques favorables chez les patients porteurs de Leucémie Myéloïdes Chronique traités avec des inhibiteurs ciblant l'activité tyrosine kinase de l'oncoprotéine de fusion BCR-ABL, les Leucémie Aigues Lymphoblastiques (LAL-B) BCR-ABL-positives restent de mauvais pronostic et requièrent de nouvelles stratégies thérapeutiques. Cette situation résulte de la présence d'autres altérations génétiques récurrentes, telle que la délétion mono- ou bi-allélique du gène codant le facteur de transcription Ikaros, observée dans plus de 83% des patients. Notre laboratoire a créé un

APA, Harvard, Vancouver, ISO, and other styles

31

Barata, João Taborda. "Interleukin-7 - mediated signaling and its role in the biology of T-cell acute lymphoblastic leukemia : potential targets for therapeutic intervention." Tese, Porto : Edição do Autor, 2002. http://catalogo.up.pt/F?func=find-b&local_base=UPB01&find_code=SYS&request=000090476.

Full text

APA, Harvard, Vancouver, ISO, and other styles

32

Arnaud, Marie-Pierre. "Physiopathologie des leucémies aigues lymphoblastiques de la lignée B à remaniement ETV6/RUNX1 : rôle de la protéine CD9." Thesis, Rennes 1, 2015. http://www.theses.fr/2015REN1S064/document.

Full text

Abstract:

Malgré l'amélioration des traitements, environ 20% des patients atteints de leucémie aigue lymphoblastiques (LAL) rechutent dans la moelle osseuse ou dans des sites extra-médullaires tels que les ovaires et les testicules, ce qui est particulièrement fréquent dans les rechutes tardives de LAL-B présentant un remaniement ETV6/RUNX1. Les travaux réalisés par Virginie Gandemer en 2007, ont montré que l'expression de CD9 permettait de distinguer les leucémies ETV6/RUNX1 des autres types de leucémie. Le gène CD9 code pour une protéine de la famille des tétraspanines dont l'expression a été corrélée

APA, Harvard, Vancouver, ISO, and other styles

33

Ribera, Salas Jordi. "Implicación de las alteraciones en el número de copias en el pronóstico y progresión de la leucemia aguda linfoblástica de línea B del adulto." Doctoral thesis, Universitat Autònoma de Barcelona, 2017. http://hdl.handle.net/10803/456036.

Full text

Abstract:

El 75% de los pacientes con leucemia aguda linfoblástica (LAL) tiene alteraciones cromosómicas recurrentes (numéricas o estructurales). Dichas anomalías (alteraciones primarias) tienen valor pronóstico independiente de otras variables y ello se tiene en cuenta para administrar un tratamiento adaptado al riesgo de cada leucemia. Sin embargo, el impacto pronóstico que pueden tener las alteraciones secundarias (p.ej. mutaciones puntuales o alteraciones en el número de copias) no está tan claro. Es probable que éstas jueguen un papel importante en la respuesta al tratamiento, ya que no todos los p

APA, Harvard, Vancouver, ISO, and other styles

34

St-Denis, Emily Jean. "The progression of precursor B cell acute lymphoblastic leukemia in murine models." 2005. http://link.library.utoronto.ca/eir/EIRdetail.cfm?Resources__ID=370355&T=F.

Full text

APA, Harvard, Vancouver, ISO, and other styles

35

Chen, Yen-Ju, and 陳衍儒. "Investigating the Variation of Transcription Factor PAX5 in Childhood B-Acute Lymphoblastic Leukemia." Thesis, 2010. http://ndltd.ncl.edu.tw/handle/37840370964107052358.

Full text

Abstract:

碩士<br>臺灣大學<br>醫學檢驗暨生物技術學研究所<br>98<br>PAX5 (Paired box 5), a member of PAX gene family, is expressed in the central nervous and the hematopoietic systems and is known to play an important role in B cell commitment. Childhood acute lymphoid leukemia (ALL) is a malignant disease resulting from uncontrolled proliferation of lymphoid progenitors. In previous large-scaled study, the PAX5 gene was the most frequent target of somatic mutation, being altered in about 30% in both pediatric and adult patients with B-ALL. However, whether PAX5 mutation plays an important role in B-ALL leukemogenesis remai

APA, Harvard, Vancouver, ISO, and other styles

36

Giada, Dal Collo. "THE PIVOTAL ROLE OF NOTCH SIGNALING IN B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA (B-ALL) CHEMOSENSITIVITY." Doctoral thesis, 2020. http://hdl.handle.net/11562/1017754.

Full text

Abstract:

Growing evidence suggests that Notch signaling pathway can modulate drug response in hematological malignancies including T-ALL, B-CLL and AML. In B-ALL we have previously demonstrated that Notch3 and Notch4 support survival of primary B-ALL cells, suggesting a role for Notch signaling in drug response. Here, we used in vitro, in silico, and in vivo approaches to comprehensively the role of Notch pathway in B-ALL pathogenesis in terms of prognosis, proliferation, survival and drug response. B-ALL cell lines were obtained from ATCC, while B-ALL primary cells were isolated from bone marrow or pe

APA, Harvard, Vancouver, ISO, and other styles

37

Healy, Jasmine. "Alternative strategies for deciphering the genetic architecture of childhood Pre-B acute lymphoblastic leukemia." Thèse, 2010. http://hdl.handle.net/1866/4665.

Full text

Abstract:

La leucémie lymphoblastique aigüe (LLA) est une maladie génétique complexe. Malgré que cette maladie hématologique soit le cancer pédiatrique le plus fréquent, ses causes demeurent inconnues. Des études antérieures ont démontrées que le risque à la LLA chez l’enfant pourrait être influencé par des gènes agissant dans le métabolisme des xénobiotiques, dans le maintient de l’intégrité génomique et dans la réponse au stress oxydatif, ainsi que par des facteurs environnementaux. Au cours de mes études doctorales, j’ai tenté de disséquer davantage les bases génétiques de la LLA de l’enfant en postu

APA, Harvard, Vancouver, ISO, and other styles

38

Fernandes, Mónica Alexandra Teotónio. "The role of lymphotoxin-B receptor signaling in t-cell acute lymphoblastic leukemia development." Master's thesis, 2010. http://hdl.handle.net/10400.1/2407.

Full text

Abstract:

Dissertação de mest., Ciências Biomédicas, Faculdade de Ciências e Tecnologia, Univ. do Algarve, 2010<br>A leucemia linfoblástica aguda de linfócitos T (LLA-T) é uma patologia hematológica maligna que afecta essencialmente crianças e adultos jovens e é fatal na ausência de um diagnóstico precoce e uma terapêutica apropriada. Sabe-se que a LLA-T tem origem em precursores dos linfócitos T, também designados por timócitos, que sofrem um bloqueio da diferenciação e expansão clonal durante o seu desenvolvimento no timo. As células imaturas transformadas acabam por entar na corrente sanguínea e inva

APA, Harvard, Vancouver, ISO, and other styles

39

Chang, Pei-Yun. "NF-[kappa]B superinduction : a mechanism to promote apoptosis resistance in human T-acute lymphoblastic leukemia cells /." 2006. http://catalog.hathitrust.org/api/volumes/oclc/85784145.html.

Full text

APA, Harvard, Vancouver, ISO, and other styles

40

Managò, Stefano. "A reliable Raman-spectroscopy-based approach for diagnosis, classification and follow-up of B-cell acute lymphoblastic leukemia." Tesi di dottorato, 2016. http://www.fedoa.unina.it/10938/1/StefanoManag%C3%B2_Thesis_TIMSI_.pdf.

Full text

Abstract:

The aim of my PhD research project was to develop an advanced optical technique, based on Raman Spectroscopy (RS) and its integration with other optical (e.g. fluorescence microscopy, flow cytometry, Raman imaging) and biological modalities (e.g. Western Blotting), in order to provide a fast and reliable procedure for identification and classification of single cells (hemogram) from peripheral blood of healthy donors as well as of cancer B-ALL patients. The work can be divided into three main parts: • Deep study of Raman spectroscopy literature with particular attention to its sensitivity, s

APA, Harvard, Vancouver, ISO, and other styles

41

NWABO, KAMDJE Armel Herve'. "ROLE OF NOTCH SIGNALING PATHWAY IN THE INTERACTION BETWEEN B-ACUTE LYMPHOBLASTIC LEUKEMIA CELLS AND BONE MARROW MESENCHYMAL STROMAL CELLS." Doctoral thesis, 2011. http://hdl.handle.net/11562/348847.

Full text

Abstract:

La leucemia linfoblastica acuta B (B-ALL) è il tipo più comune di leucemia acuta che si sviluppa nel midollo osseo. Mentre esiste molta letteratura sui dati inerenti il ruolo della segnalazione di Notch nella leucemia linfoblastica acuta T in biologia, l'importanza di questo stradino molecolare per lo sviluppo delle cellule di B-ALL nel midollo osseo non era finora noto. In questo studio, abbiamo utilizzato anticorpi neutralizzanti di Notch ed l’ inibitori della gamma-secretasi (GSI XII) per analizzare il ruolo del percorso della segnalazione di Notch nella promozione di B-ALL umane sopravviss

APA, Harvard, Vancouver, ISO, and other styles

42

Perova, Tatiana. "Characterization of Signal Transduction Abnormalities Revealed Spleen Tyrosine Kinase as a Therapeutic Target in High-risk Precursor B Cell Acute Lymphoblastic Leukemia." Thesis, 2013. http://hdl.handle.net/1807/65500.

Full text

Abstract:

Currently, the intensive chemotherapy remains the first line treatment for B cell acute lymphoblastic leukemia (B-ALL). Although these regimens have significantly improved patient outcomes, their use is associated with debilitating morbidities and fatal relapses, highlighting the great need in new agents that target essential survival signals in leukemia. Thus, the overall goal of my project was to gain insights into the signaling abnormalities that regulate aberrant proliferation and survival of B-ALL cells in an effort to identify novel targets in this malignancy. This study demonstrated tha

APA, Harvard, Vancouver, ISO, and other styles

43

Plesa, Maria. "Genetic predisposition to corticosteroid : related complications of childhood Acute Lymphoblastic Leukemia (cALL) treatment." Thèse, 2017. http://hdl.handle.net/1866/19447.

Full text

Abstract:

L’ostéonécrose (ON) et les fractures (FR) sont des complications qui prennent de plus en plus place dans le traitement pédiatrique de la leucémie aiguë lymphoblastique (LAL). L’ON peut être causée par différents facteurs, dont principalement l’utilisation de glucocorticoïdes. Les glucocorticoïdes sont administrés lors du traitement de la leucémie dans le but d’initier l’apoptose des cellules malignes tout en ayant un effet anti-inflammatoire. Cependant, l’utilisation de ces corticostéroïdes comprend des effets secondaires sérieux, notamment le développement d’ostéonécrose. Des variantes généti

APA, Harvard, Vancouver, ISO, and other styles

44

"Breaking the Senescence: Inhibition of ATM Allows S9 Cells to Re-Enter Cell Cycle." Master's thesis, 2011. http://hdl.handle.net/2286/R.I.14447.

Full text

Abstract:

abstract: The Philadelphia chromosome in humans, is on oncogenic translocation between chromosomes 9 and 22 that gives rise to the fusion protein BCR-Abl. This protein is constitutively active resulting in rapid and uncontrolled cell growth in affected cells. The BCR-Abl protein is the hallmark feature of chronic myeloid leukemia (CML) and is seen in Philadelphia-positive (Ph+) acute lymphoblastic leukemia (ALL) cases. Currently, the first line of treatment is the Abl specific inhibitor Imatinib. Some patients will, however, develop resistance to Imatinib. Research has shown how transformation

APA, Harvard, Vancouver, ISO, and other styles

45

Dobiášová, Alena. "Molekulární charakterizace nového subtypu dětské Akutní lymfoblastické leukémie s liniovým přesmykem v časné fázi léčby onemocnění." Master's thesis, 2014. http://www.nusl.cz/ntk/nusl-332193.

Full text

Abstract:

Leukemia is the most common malignant disease in children patients. In our laboratory (CLIP) a novel subtype of B-cell precursor Acute Lymphoblastic Leukemia (BCP-ALL) with lineage switch during early phase of treatment towards myeloid lineage (swALL) was recently documented. SwALL incidence is almost 4 % of all BCP-ALLs (Slámová et al., 2014). DNA methylation (presence of 5-methylcytosine) is together with post-translational histone modifications and non- coding RNAs an epigenetic mechanism which regulates gene expression without changes of genetic code. DNA methylation is easily detected by

APA, Harvard, Vancouver, ISO, and other styles

46

Woodcroft, MARK. "TOWARDS A B-LYMPHOID MODEL OF E2A-PBX1-MEDIATED LEUKEMOGENESIS: EVALUATING THE IMPACT OF HEMATOPOIETIC CELL OF ORIGIN ON THE TRANSFORMATION PROPERTIES OF A LEUKEMOGENIC TRANSCRIPTION FACTOR." Thesis, 2013. http://hdl.handle.net/1974/8243.

Full text

Abstract:

The t(1;19) chromosomal translocation is present in 5% of acute lymphoblastic leukemia (ALL) cases and leads to expression of the oncogenic transcription factor, E2A-PBX1. Although t(1;19) is exclusively associated with pre-B ALL in clinical cases, murine models produce myeloid or T-lymphoid leukemias, which are not representative of the clinical disease. In this work, we have advanced progress towards the development an E2A-PBX1-driven experimental leukemia model. We initially determined that lineage-negative (lin-) hematopoietic progenitors expressing E2A-PBX1 expression fail to repopulate t

APA, Harvard, Vancouver, ISO, and other styles

47

Liu, Tingyu. "Examining Glucose Metabolism in Survival and Proliferation of B Cell Derived Leukemia." Diss., 2014. http://hdl.handle.net/10161/9410.

Full text

Abstract:

<p>It has been long known that many types of cancers have high metabolic requirements and use reprogrammed metabolism to support cellular activities. The first identified metabolic alteration in cancer cells was elevated glucose uptake, glycolysis activity and lactate production even in the presence of oxygen. This metabolic program, termed aerobic glycolysis or the Warburg effect, provides cells with energy as well as biosynthetic substrates to sustain cell survival and rapid cell proliferation. Cancer metabolism is closely linked to genetic mutations and oncogenic signaling pathways, such as

APA, Harvard, Vancouver, ISO, and other styles

48

Mahl, Sarah Elisabeth. "The role of TAL1 and the atypical NF-KB heterodimer p65/c-Rel in T-cell acute lymphoblastic leukemia." 2013. http://liblink.bsu.edu/uhtbin/catkey/1728249.

Full text

Abstract:

T-ALL accounts for 15% of childhood leukemias and approximately 60% of patients overexpress TAL1. TAL1/SCL encodes a transcription factor that regulates hematopoiesis by dimerizing with additional transcription factors including E12, E47, and GATA-1. TAL1 has also been found to repress expression of NF-κB1, potentially promoting formation of an NF-κB p65/c-Rel heterodimer that encourages cell survival by up-regulating IAPs and IκB. However, the correlation between TAL1 and p65/c-Rel expression and their effects on downstream targets like IKK, IκB, and other anti-apoptotic proteins is poorly un

APA, Harvard, Vancouver, ISO, and other styles

49

Oliveira, Mariana Lobato de 1991. "Determining the prognostic significance of PI3K/Akt/mTOR and JAK/STAT5 signaling pathways in pediatric acute lymphoblastic leukemia using single-cell analysis." Master's thesis, 2015. http://hdl.handle.net/10451/23456.

Full text

Abstract:

Tese de mestrado, Oncobiologia, Faculdade de Medicina, Universidade de Lisboa, 2015<br>Acute lymphoblastic leukemia (ALL) is the most frequent childhood malignancy and it is characterized by the accumulation of immature lymphoid cells within the bone marrow and lymphoid tissues. Approximately 85% of pediatric ALL patients have a B-cell phenotype (B-ALL), and, despite significant improvements in treatment outcome, around 10-20% still relapse. Thus, there is a clear need for new prognostic factors capable of accurately predicting response to therapy. PI3K/Akt/mTOR and JAK/STAT5 pathways are ext

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!